Results 171 to 180 of about 19,412 (203)
BCL-2/BCL-xL inhibitor pelcitoclax with osimertinib for <i>EGFR</i>-mutated advanced non-small-cell lung cancer: a phase 1b trial. [PDF]
J Immunother CancerMa Y +16 more
europepmc +1 more source
ctDNA-based detection of residual disease: implications for management of non-metastatic NSCLC. [PDF]
Front OncolLeclercq C +5 more
europepmc +1 more source
Roles of myeloperoxidase and the AMPK/PI3K/AKT/eNOS pathway in osimertinib-induced cardiotoxicity: multilevel evidence from disequilibrium analysis, network pharmacology, mendelian randomization, and animal experiments. [PDF]
Front PharmacolShi J +6 more
europepmc +1 more source
Reactions Weekly, 2018 Epidermal growth factor receptor (EGFR)-mutated (exons 18-21) advanced non-small cell lung cancers (NSCLCs) are generally characterized by exquisite sensitivity to treatment with an EGFR-tyrosine kinase inhibitor (-TKI). First-generation or reversible EGFR-TKIs include gefitinib and erlotinib, while, more recently, second-generation or irreversible ...
Malapelle, Umberto +11 more
core +12 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Combined osimertinib, dabrafenib and trametinib treatment for advanced non-small-cell lung cancer patients with an osimertinib-induced BRAF V600E mutation [PDF]
Lung Cancer, 2020 INTRODUCTION: Previous studies have reported an acquiredBRAF V600E mutation as a potential resistance mechanism to osimertinib treatment in advanced NSCLC patients with an activating mutation in EGFR.
Anthonie van der Wekken +2 more
exaly +3 more sources